Varian Puts Research Tools in the Cloud to Speed Development of Next Generation Cancer Treatment Technologies | Varian

{ "pageType": "news-article", "title": "Varian Puts Research Tools in the Cloud to Speed Development of Next Generation Cancer Treatment Technologies", "articleDate": "September 01, 2015", "introText": "", "category": "Oncology" }

Varian Puts Research Tools in the Cloud to Speed Development of Next Generation Cancer Treatment Technologies

PALO ALTO, Calif., Sept. 1, 2015 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR) has added a new cloud-based toolkit to the company's OncoPeer™ interactive online forum, making development tools available for research that has the potential to lead to next generation cancer treatment technologies.  

Varian's new Developer Cloud houses digital tools like information about TrueBeam® Developer Mode, and cloud-based applications for managing Developer Mode and simulating treatments. It is part of the company's overall objective to empower research-oriented clinical teams to accelerate the development of new treatment techniques and processes designed to improve outcomes for cancer patients. 

"When Varian introduced the TrueBeam platform in 2010, we included Developer Mode, an optional non-clinical development tool for researchers to use in pioneering and prototyping new treatment techniques," said Corey Zankowski, vice president of products and strategic portfolio management. "Many important advances have been enabled by the use of this and other Varian development tools. Developer Cloud was created to aggregate these developer tools in one place so researchers can easily access what they need. Researchers can also use the OncoPeer forum to engage in discussions with other users of the research tools, to share best practices."

In a separate development, the OncoPeer online forum, first launched last March in select geographic areas, is now accessible to Varian customers worldwide. Since March, users have established discussion groups on topics like oncology analytics, knowledge-based treatment planning, treatment planning using Eclipse™ software, and the physics of radiotherapy.  One discussion group focuses on how to use Varian's ARIA® information system to manage a medical oncology department. Other groups share information about Varian treatment delivery platforms.

"OncoPeer is a place for customers to find others who use Varian technology and learn from one another," said Sukhveer Singh, vice president, Varian Oncology Continuum Solutions. "With the addition of the Developer Cloud, OncoPeer is now a resource for the research community as well." 

Varian held an online seminar about Navigating OncoPeer last May. Interested clinicians can view a replay of the webcast at this registration website. Customers can access OncoPeer at (registration required).

About Varian Medical Systems
Varian Medical Systems, Inc., of Palo Alto, California, focuses energy on saving lives by equipping the world with advanced technology for fighting cancer and for X-ray imaging. The company is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiation. The company provides comprehensive solutions for radiotherapy, radiosurgery, proton therapy and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is also a premier supplier of X-ray imaging components, including tubes, digital detectors, and image processing software and workstations for use in medical, scientific, and industrial settings, as well as for security and non-destructive testing. Varian Medical Systems employs approximately 6,800 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit or follow us on Twitter.

Forward-Looking Statements
Except for historical information, this news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning industry outlook, including growth drivers; the ability of the company's technology and products to treat cancer or improve outcomes; and any statements using the terms "intended to," "potential," "can," "would," or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company's actual results to differ materially from those anticipated. Such risks and uncertainties include the effect of global economic conditions; demand for the company's products; the company's ability to develop, commercialize, and deploy new products; the company's ability to meet legal and regulatory requirements; changes in the legal or regulatory environment; and the other risks listed from time to time in the company's filings with the Securities and Exchange Commission, which by this reference are incorporated herein. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.

Press Contact

Meryl Ginsberg
Varian Medical Systems
+1 (650) 424-6444


SOURCE Varian Medical Systems